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r.batterham@ucl.ac.ukSummarySleeve gastrectomy (SG) is the second most commonly performed bariatric procedure worldwide. Altered circulating gut
hormones have been suggested to contribute post-operatively to appetite suppression, decreased caloric intake and weight
reduction. In the present study, we report a 22-year-old woman who underwent laparoscopic SG for obesity (BMI 46 kg/m2).
Post-operatively, she reported marked appetite reduction, which resulted in excessive weight loss (1-year post-SG: BMI
22 kg/m2, weight loss 52%, O99th centile of 1-year percentage of weight loss from 453 SG patients). Gastrointestinal (GI)
imaging, GI physiology/motility studies and endoscopy revealed no anatomical cause for her symptoms, and psychological
assessments excluded an eating disorder. Despite nutritional supplements and anti-emetics, her weight loss continued
(BMI 19 kg/m2), and she required nasogastric feeding. A random gut hormone assessment revealed high plasma peptide
YY (PYY) levels. She underwent a 3 h meal study following an overnight fast to assess her subjective appetite and circulating
gut hormone levels. Her fasted nausea scores were high, with low hunger, and these worsened with nutrient ingestion.
Compared to ten other post-SG female patients, her fasted circulating PYY and nutrient-stimulated PYY and active
glucagon-like peptide 1 (GLP1) levels were markedly elevated. Octreotide treatment was associated with suppressed
circulating PYY and GLP1 levels, increased appetite, increased caloric intake and weight gain (BMI 22 kg/m2 after 6 months).
The present case highlights the value of measuring gut hormones in patients following bariatric surgery who present with
anorexia and excessive weight loss and suggests that octreotide treatment can produce symptomatic relief andweight regain
in this setting.http://www.edmcasereports.com
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† Roux-en-Y gastric bypass and SG produce marked sustained weight reduction. However, there is a marked individual
variability in this reduction, and post-operative weight loss follows a normal distribution with extremes of ‘good’
and ‘poor’ response.
† Profound anorexia and excessive weight loss post-SG may be associated with markedly elevated circulating fasted
PYY and post-meal PYY and GLP1 levels.
† Octreotide treatment can produce symptomatic relief and weight regain for post-SG patients that have an extreme
anorectic and weight loss response.
† The present case highlights the value of measuring circulating gut hormone levels in patients with post-operative
anorexia and extreme weight loss.Background
Bariatric surgery is the most effective treatment for severe
obesity; it produces marked sustained weight loss, reduced
obesity-associated co-morbidities (1) and decreased
mortality (2). Roux-en-Y gastric bypass (RYGB) and sleeve
gastrectomy (SG), the most common procedures that are
undertaken globally (3), are known to reduce appetite and
decrease caloric intake. The mechanisms that mediate
these changes remain to be clarified (4). However, post-
operative changes in circulating gut hormones, in
particular, the anorectic hormones peptide YY (PYY) and
glucagon-like peptide 1 (GLP1) and the orexigenic
hormone ghrelin, have been suggested to play causal
roles (5). Weight loss after RYGB and SG follows a normal
distribution (6), with ‘good responders’ and ‘poor
responders’ exhibiting differential appetite and gut
hormone profiles (7) (8).120 Patient
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Figure 1
Histogram of the percentage of weight loss at 1-year post-surgery for all of
the sleeve gastrectomies performed by our bariatric unit (nZ453). The
vertical line at the extreme end of the normal distribution shows the
percentage of weight loss of the case that represented a 52% body
weight loss.Case presentation
A 22-year-old woman underwent an uneventful laparo-
scopic SG for severe obesity (weight 135 kg, BMI
46 kg/m2). Her initial post-operative course was unremark-
able, except she reportedmarked loss of appetite. One-year
post-SG, she reported continued anorexia, her weight had
decreased to 64.6 kg, and her BMI had decreased to
22 kg/m2; this represented a 52% body weight loss,
which is at the extreme end of the normal distribution
of 1-year post-operative percentage of weight loss for SG
patients (nZ453) in our bariatric unit (Fig. 1). She did not
suffer from flushing or diarrhoea. She was commenced
on anti-emetics and received increased dietetic support,
including advice on high-energy oral supplements.http://www.edmcasereports.comHowever, her weight loss continued, and she developed
continuous profound nausea with occasional vomiting.Investigation
The patient underwent computed tomography (CT)
imaging of her abdomen and pelvis, barium swallow
and follow-through, oesophageal–gastro-duodenoscopy,
oesophageal motility analysis and pH studies, all of which
were normal. Psychological assessments excluded an
eating disorder. Her symptoms worsened, her weight
decreased to 55.8 kg, her BMI decreased to 19.5 kg/m2
and she required in-patient management with nasogastric
feeding. A random gut hormone assessment revealed high
circulating PYY levels (1200 pg/ml). Her fasted plasma2
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Figure 2
Graphs of the response to the test meal (200 kcal for case and 500 kcal for
control post-SG group) administered at time 0. (A) Subjective sickness score
and (B) subjective hunger score (both assessed with the VAS), (C) plasma
total PYY levels and (D) active GLP1 levels. Blue line and filled blue circles,
case baseline meal; red line and open red squares, case treated with 100 mg
octreotide three times a day; black dotted line and open triangles,
ten female control post-SG patients.
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levels were normal (chromogranin A 51 ng/ml (upper limit
of normal 100 ng/ml) and 5HIAA!4 ng/ml (upper limit of
normal 13.4 ng/ml)) (9). A 3 h liquidmeal study (2 kcal/ml,
ResourcePlus Nestle, Nestle Nutrition, Croydon, UK) after
an overnight 12 h fast was undertaken to assess her
subjective appetite and circulating PYY, GLP1 and ghrelin
responses. Because of nausea, she was only able to tolerate
100 ml instead of our standard meal of 250 ml. Blood
samples and appetite visual analogue scales (VASs) were
taken pre-meal and then at 15, 30, 60, 90, 120, 150 and
180 min post-meal. In order to preserve the integrity of
labile gut hormone, appropriate preservatives/inhibitors
were added and blood was processed according to our
published protocols (10). She was commenced
on octreotide, a somatostatin analogue, 100 mg sub-
cutaneously three times a day, which resulted in an
immediate appetite improvement and nausea resolution.
The 100 ml meal study was repeated after 14 days of
octreotide treatment. Our patient’s gut hormone results
were compared to those obtained from ten female patients
3months post-SG (control post-SG group) who underwent
a 250 ml liquid meal study. All of the patients gave written
informed consent.
Plasma total PYY, active GLP1, acyl-ghrelin, total
ghrelin and insulin were assayed in duplicate by
commercially available ELISAs (Millipore, Watford, UK),
and plasma glucose was measured by a Yellow Springs
Instrument glucose analyser (Yellow Springs, OH, USA).
At the start of her baseline study, despite a 12 h fast, she
reported high nausea and low hunger. Meal ingestion
increased her nausea and further suppressed her hunger
(Fig. 2A and B). Her fasted circulating PYY levels were
fivefold higher than those of control post-SG patients, and
they increased further following nutrient ingestion
(Fig. 2C). The PYY area under the curve (AUC) for her
baseline meal was 5.5-fold greater than our control post-
SG group’s PYY AUC, despite our controls consuming two-
and-a-half times more calories. Her fasted active GLP1
levels were comparable to those of the control post-SG
patients (Fig. 2D). However, her peak active GLP1 was
markedly elevated at 15 min post-meal (Fig. 2D). Despite
her high nutrient-stimulated GLP1 levels, her nutrient-
stimulated plasma insulin levels were not unduly elevated
(plasma insulin levels at 15 min post-meal: patient
31.5 pmol/l; control post-SG 23G2.4 pmol/l).
Both her acyl-ghrelin and total ghrelin levels were
undetectable in the fasted and fed states, in contrast to
the detectable levels in the control post-SG group. On
octreotide treatment, her hunger increased and her nauseahttp://www.edmcasereports.comresolved (Fig. 2A and B). Her circulating fasted and
nutrient-stimulated PYY (Fig. 2C), active GLP1 (Fig. 2D)
and insulin levels were suppressed (15 min post-meal
3.2 pmol/l). Her plasma acyl-ghrelin and total ghrelin
levels remained undetectable.Treatment
The patient continued with 100 mg octreotide injected
subcutaneously three times a day for 4 months and was
then switched to long-acting octreotide, 20 mg sando-
statin LAR, administered intramuscularly every 3 weeks.
During this time, her nausea and vomiting completely
resolved, her appetite increased and her weight increased
to 63.4 kg.Discussion
SG, which involves removing 90% of the gastric fundus
while leaving the rest of the gastrointestinal tract intact,
has recently been advocated as a ‘stand-alone’ bariatric
procedure. However, it has become apparent, at least in
the short- to medium-term, that the weight loss and
metabolic benefits post-SG are comparable to RYGB (11).
Consequently, the number of patients that underwent SG
globally per annum increased from w25 000 in 2008 to
95 000 in 2011 (3). Furthermore, research efforts have
identified that mechanisms other than restriction and/or3
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and weight-loss-independent glycaemic improvements
of these two procedures (5). Decreased energy intake, as
a consequence of reduced hunger, altered food preferences
and changes in food reward, is a key driver of the sustained
weight loss that follows SG and RYGB. Post-operatively,
nutrient-stimulated circulating levels of the anorectic gut
hormones PYY and GLP1 are markedly increased, whereas
plasma levels of the orexigenic hormone ghrelin are
reduced post-SG and are lower than those seen after
RYGB (12). These post-operative circulating gut hormone
changes have been suggested to contribute to the altered
feeding behaviour (5). We and others have reported that
weight loss following SG and RYGB is variable and follows
a normal distribution (6) (13). Interestingly, ‘poor’ and
‘good’ weight loss responders exhibit differential appetite
and gut hormone changes post-surgery (7) (8).
We report the first case of a patient post-SG with
profound anorexia and excessive weight loss coupled with
high fasted PYY levels and elevated nutrient-stimulated
GLP1 and PYY levels. Unlike in our control post-SG
patients, we were unable to detect either acyl-ghrelin or
total ghrelin in our patient at baseline. Previously, we have
shown that exogenous PYY administration suppresses
circulating ghrelin levels (14) (15), and a similar
mechanism may be at work in the present case, with
high endogenous PYY levels suppressing ghrelin. Our
patient reported disabling nausea with occasional vomit-
ing, symptoms that are entirely consistent with elevated
PYY and GLP1 levels (16) (17). Studies that were
undertaken in ‘poor’ as compared to ‘good’ weight loss
responders have suggested that variability in post-
operative gut hormone responses may contribute to
variable weight loss outcomes (7) (8). The present case
further supports this hypothesis. However, the biological
mechanisms that underlie post-operative gut hormone
variability remain to be elucidated. High nutrient-
stimulated GLP1 levels have been suggested by some but
not all researchers to contribute to post-RYGB hyperinsu-
linaemic hypoglycaemia (18), a complication that affects
w0.1% of patients post-RYGB (19). Octreotide adminis-
tration produces symptomatic relief in some of these
patients (20), and in others RYGB reversal has been
beneficial (21). However, surgical reversal is not possible
following SG. Interestingly, there have been reports of
resolution of post-RYGB hyperinsulinaemic hypoglycae-
mia that have allowed medical therapy to be discontinued
(21). Possible future outcomes for our patient are that her
gut hormone profile could ‘normalise’, which would allow
the withdrawal of octreotide therapy or that an increasedhttp://www.edmcasereports.comunderstanding of enteroendocrine cell biologymay enable
the selective targeting of her GLP1- and PYY-producing
enteroendocrine L-cells. There are some limitations to the
present study. We compared the case patient’s nutrient-
stimulated gut hormone levels to those measured in a
relatively small number of control patients who were
3 months post-SG. Thus, the case patient had a lower BMI
and greater weight loss as compared to the control post-SG
group. These differences in weight loss and interval post-
SG could have impacted the circulating gut hormone
levels (22). In addition, the case patient could only tolerate
100 ml (200 kcal) of the liquid test meal as compared to
the 250 ml (500 kcal) consumed by the control post-SG
group, which makes a direct comparison difficult.
However, given that nutrient-stimulated plasma GLP1
and PYY levels are proportionate to the calorie load
consumed, it is likely that the matching of the caloric
loads would have further increased the difference between
the case patient and the control group.Conclusion
The present case highlights the value of measuring gut
hormones in patients following SG who present with
anorexia and excessive weight loss and suggests that
octreotide treatment can produce symptomatic relief and
weight regain for patients in this challenging clinical
setting.Declaration of interest
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